Huang Qi-chao, Lei Xiao-ying, Liu Yan, Sui Wen-jun, Li Shen, Zhang Ying-qi, Yan Zhen
State Key Laboratory of Tumor Biology; Department of Pharmacogenomics, the Fourth Military Medical University, Xi'an 710032, China.
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2010 May;26(5):412-5.
Search for key molecules to influence the tumor-targeted IFN-alpha2a-NGR anti-tumor sensitivity through signaling pathway study. Try to enhance the antitumor efficacy of IFN-alpha2a-NGR.
MTT method was used to determine the growth inhibitory effects of IFN-alpha2a-NGR on A549 and MKN-45 cells. Flow cytometry and Western blot were employed to detect the expression of STAT1, p-STAT1, p53, OAS and SOCS1; SOCS1 gene knock down was carried out by synthesized siRNA.
When stimulated with IFN-alpha2a-NGR, the increased expression of STAT1, p-STAT1, p53, OAS and SOCS1 were observed in A549 cells, but only SOCS1 was notably increased in MKN-45 cells. The proliferation inhibition ability of MKN-45 to IFN-alpha2a-NGR was promoted by SOCS1 knocking down. (the inhibition rate was enhanced from 14.69%+/-1.05% to 36.97%+/-2.05%).
This study has further demonstrated that there were no differences on antitumor effects between IFN-alpha2a-NGR and IFN-alpha2a on cell or molecular level. Besides interferon-alpha receptor (IFNAR) which has been demonstrated before, p-STAT1, p53 and SOCS1 were important determinants of tumor resistance to IFNs therapy. The antitumor efficacy of IFN-alpha2a-NGR can be enhanced by RNA interference. These results might be helpful for the further development of IFN-alpha2a-NGR.
通过信号通路研究寻找影响肿瘤靶向性干扰素α2a-NGR抗肿瘤敏感性的关键分子,尝试增强干扰素α2a-NGR的抗肿瘤疗效。
采用MTT法测定干扰素α2a-NGR对A549和MKN-45细胞的生长抑制作用。运用流式细胞术和蛋白质免疫印迹法检测信号转导和转录激活因子1(STAT1)、磷酸化信号转导和转录激活因子1(p-STAT1)、p53、2'-5'-寡腺苷酸合成酶(OAS)和细胞因子信号转导抑制因子1(SOCS1)的表达;通过合成的小干扰RNA(siRNA)敲低SOCS1基因。
用干扰素α2a-NGR刺激时,A549细胞中STAT1、p-STAT1、p53、OAS和SOCS1的表达均增加,但MKN-45细胞中只有SOCS1显著增加。敲低SOCS1可增强MKN-45对干扰素α2a-NGR的增殖抑制能力(抑制率从14.69%±1.05%提高到36.97%±2.05%)。
本研究进一步证明,在细胞或分子水平上,干扰素α2a-NGR与干扰素α2a的抗肿瘤作用无差异。除了先前已证实的干扰素α受体(IFNAR)外,p-STAT1、p53和SOCS1是肿瘤对干扰素治疗耐药的重要决定因素。RNA干扰可增强干扰素α 2a-NGR的抗肿瘤疗效。这些结果可能有助于干扰素α2a-NGR的进一步研发。